Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: The RETAIN study

Ophthalmology

Volumn 121, Issue 1, 2014, Pages 209-219

  Campochiaro, Peter A ^a   Sophie, Raafay ^a   Pearlman, Joel ^b   Brown, David M ^c   Boyer, David S ^d   Heier, Jeffrey S ^e   Marcus, Dennis M ^f   Feiner, Leonard ^g   Patel, Arun ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Retina Consultants   (United States)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

^e Ophthalmic Consultant of Boston   (United States)

^f Southeast Retina Center   (United States)

^g Retina Associates of New Jersey   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB;

ADULT; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; FEMALE; FOLLOW UP; HEMIRETINAL VEIN OCCLUSION; HUMAN; LASER COAGULATION; MALE; MIDDLE AGED; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA MACULA EDEMA; RETINA TEAR; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY; VISUAL IMPAIRMENT; VITREOUS HEMORRHAGE;

AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINAL VEIN OCCLUSION; SINGLE-BLIND METHOD; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84891631064     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2013.08.038     Document Type: Article

References (11)

1. P.A. Campochiaro, G. Hafiz, and S.M. Shah et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator Mol Ther 16 2008 791 799
2. D.M. Brown, P.A. Campochiaro, and R.P. Singh CRUISE Investigators Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point of a phase III study Ophthalmology 117 2010 1124 1133
3. P.A. Campochiaro, J.S. Heier, and L. Feiner BRAVO Investigators Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary endpoint results of a phase III study Ophthalmology 117 2010 1102 1112
4. J.S. Heier, P.A. Campochiaro, and L. Yau et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial Ophthalmology 119 2012 802 809
5. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
6. P.A. Campochiaro, D.M. Brown, and C.C. Awh et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study Ophthalmology 118 2011 2041 2049
7. D.M. Brown, P.A. Campochiaro, and R.B. Bhisitkul et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study Ophthalmology 118 2011 1594 1602
8. D.M. Brown, J.S. Heier, and W.L. Clark et al. Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 COPERNICUS Study Am J Ophthalmol 155 2013 429 437
9. F.G. Holz, J. Roider, and Y. Ogura et al. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study Br J Ophthalmol 97 2013 278 284
10. Sophie R, Hafiz G, Scott A, et al. Progression of retinal nonperfusion in patients with retinal vein occlusion. Am J Ophthalmol. In press.
11. P.A. Campochiaro, R.B. Bhistikul, H. Shapiro, and R.G. Rubio Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion Ophthalmology 120 2013 795 802